Oral valganciclovir is safe and effective as preemptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation

被引：0
|
作者：
Ayala, E [1 ]
Greene, J [1 ]
Sandin, R [1 ]
Perkins, J [1 ]
Field, T [1 ]
Tate, C [1 ]
Goldstein, SC [1 ]
机构：
[1] H Lee Moffit Canc Ctr & Res Inst, Tampa, FL USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2004年 / 10卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2003.12.133
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
65
引用
收藏
页码：31 / 31
页数：1
相关论文
共 50 条
  • [1] Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation
    E Ayala
    J Greene
    R Sandin
    J Perkins
    T Field
    C Tate
    K K Fields
    S Goldstein
    [J]. Bone Marrow Transplantation, 2006, 37 : 851 - 856
  • [2] Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation
    Ayala, E
    Greene, J
    Sandin, R
    Perkins, J
    Field, T
    Tate, C
    Fields, KK
    Goldstein, S
    [J]. BONE MARROW TRANSPLANTATION, 2006, 37 (09) : 851 - 856
  • [3] Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients
    Katsuto Takenaka
    Tetsuya Eto
    Koji Nagafuji
    Kenjiro Kamezaki
    Yayoi Matsuo
    Goichi Yoshimoto
    Naoki Harada
    Maki Yoshida
    Hideho Henzan
    Ken Takase
    Toshihiro Miyamoto
    Koichi Akashi
    Mine Harada
    Takanori Teshima
    [J]. International Journal of Hematology, 2009, 89 : 231 - 237
  • [4] Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients
    Takenaka, Katsuto
    Eto, Tetsuya
    Nagafuji, Koji
    Kamezaki, Kenjiro
    Matsuo, Yayoi
    Yoshimoto, Goichi
    Harada, Naoki
    Yoshida, Maki
    Henzan, Hideho
    Takase, Ken
    Miyamoto, Toshihiro
    Akashi, Koichi
    Harada, Mine
    Teshima, Takanori
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (02) : 231 - 237
  • [5] Improving Safety of Preemptive Therapy with Oral Valganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
    Barkam, Corinna
    Kamal, Haytham
    Dammann, Elke
    Diedrich, Helmut
    Buchholz, Stefanie
    Eder, Matthias
    Krauter, Juergen
    Ganser, Arnold
    Stadler, Michael
    [J]. BONE MARROW RESEARCH, 2012,
  • [6] Valganciclovir is safe and effective as pre-emptive treatment for CMV infection in allogeneic hematopoietic stem cell transplantation.
    Pastano, Rocco
    Gigli, Federica
    Andreola, Giovanna
    Calabrese, Liliana
    Peccatori, Fedro
    Martinelli, Giovanni
    [J]. BLOOD, 2006, 108 (11) : 417B - 417B
  • [7] Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation
    Busca, A.
    de Fabritiis, P.
    Ghisetti, V.
    Allice, T.
    Mirabile, M.
    Gentile, G.
    Locatelli, F.
    Falda, M.
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2007, 9 (02) : 102 - 107
  • [8] Oral Valganciclovir As Preemptive Therapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients
    Ozkocaman, Vildan
    Ozkalemkas, Fahir
    Ali, Ridvan
    Karacan, Yasemin
    Ersal, Tuba
    Gozden, Hilmi Erdem
    Erus, Tugcan
    Kazak, Esra
    Akalin, Halis
    [J]. BLOOD, 2014, 124 (21)
  • [9] Valganciclovir is safe and effective as pre-emptive treatment for CMV reactivation in allogeneic hematopoietic stem cell transplantation
    Pastano, R.
    Gigli, F.
    Andreola, G.
    Peccatori, F. A.
    Martinelli, G.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 468 - 468
  • [10] What is the optimal dosage of valganciclovir as preemptive therapy for CMV infection in allogeneic hematopoietic SCT?
    A Candoni
    E Simeone
    M Tiribelli
    C Pipan
    R Fanin
    [J]. Bone Marrow Transplantation, 2008, 42 : 207 - 208
12345